WertQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMMittelzufluss aus Investitionstätigkeit-278 K-5 000-32 K451 K2 000416 KZahlungsströme aus der Finanzierungstätigkeit837 K2 0000002 000Freier Cashflow12.81 M-14.91 M-18.14 M-10.73 M-4.24 M-48.02 M
Barinthus Biotherapeutics plc - American Depositary Shares
Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.